Lazaridis K N, Lindor K D
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA.
Curr Gastroenterol Rep. 2000 Apr;2(2):94-8. doi: 10.1007/s11894-000-0091-z.
Primary biliary cirrhosis (PBC) is one of the most common chronic cholestatic liver diseases affecting the adult population. The clinical presentation of PBC can be diverse, ranging from the presymptomatic individual to the patient with advanced liver disease. Initial evaluation to establish diagnosis and appropriate follow-up are very important in the life-long management of these patients. The primary medical treatment in PBC should focus on reducing the rate of disease progression. To this extent, treatment with ursodeoxycholic acid has been extensively evaluated and has been shown to improve liver biochemistries and survival in patients with PBC. Secondary medical management in PBC should address the treatment of complications of chronic cholestasis, hepatic cirrhosis, and liver failure. Liver transplantation remains the only established therapeutic approach in treatment of patients with end-stage PBC and the associated complications.
原发性胆汁性肝硬化(PBC)是影响成年人群的最常见慢性胆汁淤积性肝病之一。PBC的临床表现多种多样,从无症状个体到晚期肝病患者都有。在这些患者的终身管理中,建立诊断的初始评估和适当的随访非常重要。PBC的主要药物治疗应侧重于降低疾病进展速度。在这方面,熊去氧胆酸治疗已得到广泛评估,并已证明可改善PBC患者的肝脏生化指标和生存率。PBC的二级药物管理应针对慢性胆汁淤积、肝硬化和肝衰竭并发症的治疗。肝移植仍然是治疗终末期PBC及其相关并发症患者的唯一既定治疗方法。